Metastrict

The Problem

Metastasis is responsible for up to 80% of cancer-related deaths, yet it remains one of the most underserved areas in oncology. Current cancer therapies fail to effectively address metastasis, particularly in colorectal cancer (CRC), where Stage IV survival has barely improved in decades. Key drivers of metastasis, MACC1 and S100A4, are strongly linked to poor outcomes but remain untargeted, and clinicians lack tools to identify high-risk patients early.

The Solution

Metastrict targets the root drivers of metastasis, MACC1 and S100A4 genes linked to poor survival when highly expressed, with an initial focus on colorectal cancer. The team is developing a first-in-class small molecule inhibitor that suppresses these genes, reducing tumor cell motility, proliferation, and ultimately metastasis formation. By targeting MACC1, the therapy also overcomes chemoresistance, restoring sensitivity to standard-of-care treatments.
In parallel, Metastrict is advancing a blood-based prognostic test to identify high-risk patients early, enabling better stratification and more targeted intervention.

Together, this integrated therapeutic and diagnostic (theranostic) approach enables intervention both before and after metastasis onset, fundamentally reshaping how metastatic disease is managed.

Looking for

• Investors
• Co-development partners
• Diagnostic development partner
• Pilot partner

Technology

Metastrict is also available as technology asset.

News and background